Table 1.
Baseline demographic and clinical characteristics of the haematological malignancy patients with Gram negative bacilli bacteraemia.
| Characteristics | Total n = 154 | Non-survived n = 30 (%) | Survived n = 124 (%) | p valuea |
|---|---|---|---|---|
| Age, median (range), years | 40.7 (16–76) | 47.5 (16–76) | 40.0 (16–76) | 0.31 |
| Gender | 0.76 | |||
| Male | 86 (55.8) | 18 (60.0) | 68 (54.8) | |
| Female | 68 (44.2) | 12 (40.0) | 56 (45.2) | |
| Haematological diagnosis | 0.02 | |||
| Leukaemias | 92 (59.7) | 16 (53.3) | 76 (61.3) | |
| Acute mylogenous leukaemia | 63 (40.9) | 13 (43.3) | 50 (40.3) | |
| Acute lymphocytic leukaemia | 26 (16.9) | 3 (10.0) | 23 (18.5) | |
| Chronic lymphocytic leukaemia | 3 (1.9) | 0 | 3 (2.4) | |
| Lymphoma | 30 (19.5) | 3 (10.0) | 27 (21.8) | |
| Hodgkin lymphoma | 13 (8.4) | 2 (6.7) | 11 (8.9) | |
| Non-Hodgkin lymphoma | 17 (11.0) | 1 (3.3) | 16 (12.9) | |
| Multiple myeloma | 17 (11.0) | 4 (13.3) | 13 (10.5) | |
| Aplastic anaemia | 15 (9.7) | 7 (23.3) | 8 (6.5) | |
| Hematopoietic stem cell transplantation | 47 (30.5) | 5 (16.7) | 42 (33.9) | 0.1 |
| Allogenic | 25 (16.2) | 5 (16.2) | 20 (16.1) | |
| Autologous | 22 (14.3) | 0 (0.0) | 22 (17.7) | |
| Comorbid diseases | 15 (6.7) | 5 (16.6) | 10 (8.0) | 0.17 |
| Acute renal failure | 10 (15.4) | 4 (1.9) | 6 (4.8) | |
| Graft versus host disease | 3 (1.9) | 0 (0.0) | 3 (2.4) | |
| Diabetes mellitus | 1 (0.6) | 1 (3.3) | 0 | |
| Goodpasture syndrome | 1 (0.6) | 0 (0.0) | 1 (0.8) | |
| Source of bacteremia | 0.13 | |||
| Primary bacteremia | 111(72.1) | 23 (76.7) | 88 (71.0) | |
| Catheter related | 27 (17.5) | 2 (6.7) | 25 (20.2) | |
| Other | 16 (10.3) | 5 (16.6) | 11 (8.8) | |
| Pneumonia | 5 (3.2) | 4 (13.3) | 1 (0.8) | |
| Urinary tract infection | 6 (3.9) | 1 (3.3) | 5 (4.0) | |
| Abscess | 5 | 0 (0.0) | 5 (4.0) | |
| Duration from admission to bacteremia median (days) (range) | 22.7 (1–92) | 17.0 (1–92) | 24.0 (1–55) | 0.03 |
| Corticosteroid use | 16 (10.4) | 5 (16.7) | 11 (8.9) | 0.31 |
| Neutrophil counts | 0.29 | |||
| <100 cells/mm3 | 123(79.9) | 27 (90.0) | 96 (77.4) | |
| 100–500 cells/mm3 | 13 (8.4) | 1 (3.3) | 12 (9.7) | |
| >500 cells/mm3 | 18 (11.7) | 2 (6.7) | 16 (12.9) | |
| Pitt's bacteremia score, median (range) | 1.27 (0–8) | 2.5 (0–8) | 0 (0–6) | <0.001 |
| Charlson comorbidity index, median (range) | 2.17 (0–6) | 2.0 (0–4) | 2.0 (0–6) | 0.3 |
| Severe sepsis | 44 (28.6) | 22 (73.3) | 22 (17.7) | <0.001 |
| Septic shock | 4 (2.6) | 3 (10.0) | 1 (0.8) | 0.024 |
| Enterobacteriaceae | 120 (77.9) | 18 (60.0) | 102 (82.3) | 0.017 |
| Esherichia coli | 86 | 10 | 76 | |
| Klebsiella pneumoniae | 25 | 5 | 20 | |
| Klebsiella spp. | 3 | 0 | 3 | |
| Enterobacter cloacea | 6 | 3 | 3 | |
| Glucose non-fermenting Gram negative bacilli | 34 (22.1) | 12 (40.0) | 22 (17.7) | |
| Pseudomonas aeruginosa | 15 | 3 | 12 | |
| Acinetobacter baumannii | 11 | 8 | 3 | |
| Stenotrophomonas maltophilia | 7 | 1 | 6 | |
| Burkholderia cepacia | 1 | 0 | 1 | |
| Multidrug resistant non-fermenter Gram negative bacilli (n:34) | 18 (52.9) | 9 (75.0) | 9 (40.9) | 0.12 |
| ESBL producing Enterobacteriaceae (n:120) | 40 (33.3) | 5 (27.8) | 35 (34.3) | 0.78 |
| Intensive care unit acquired bacteraemia | 12 (7.8) | 8 (26.7) | 4 (3.2) | <0.001 |
| Inappropriate empiric antibiotic treatment | 26 (16.9) | 13 (43.3) | 13 (10.5) | <0.001 |
ESBL, extended spectrum beta-lactamase.
Values are expressed as n (%) or median (25th and 75th percentiles).
a
p Value for χ2, Fisher's exact, and Mann–Whitney U test, were applicable.